The University of Texas MD Anderson Cancer Center

December 13, 2017

40% of Relapsed NHL Patients Remain Cancer-free a Year After Treatment with Kite’s Yescarta

News

More than a year after receiving the CAR T-cell therapy Yescarta (axicabtagene ciloleucel), 42 percent of the patients in the ZUMA-1 trial are still responding to the treatment, Kite Pharma announced. The Phase ... Read more

February 18, 2016February 18, 2016

In Study of Mantle Cell Lymphoma and Acute Myeloid Leukemia Samples, ONC201 Shows Promising Results

News

In a new study, researchers at the University of Texas MD Anderson Cancer Center found that ONC201, a first-in-class anticancer drug being developed in partnership with Oncoceutics Inc., caused cancer ... Read more

February 4, 2016August 23, 2016

MD Anderson Cancer Center Holds Lymphoma and Myeloma Symposium on Feb. 6

News

The University of Texas MD Anderson Cancer Center is holding a symposium for patients with lymphoma and myeloma, and for their caregivers and family members, providing all with access to the latest ... Read more

January 6, 2016January 6, 2016

Latest Lymphoma Research and Treatment Is Topic of MD Anderson Symposium

News

Lymphoma and myeloma patients, as well as their caregivers, will have the opportunity to interact with leading specialists in the field and learn of the latest developments in disease treatment and clinical research ... Read more